VistaGen Therapeutics Stock Price

0.0008 (0.15%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0128 -2.41% 0.5182 0.51 0.545 0.545 0.531 18:01:58
Bid Price Ask Price Spread Spread % News
0.519 0.54 0.021 3.89% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
691 649,673 $ 0.526218 $ 341,870 1,225,464 0.10 - 1.4862
Last Trade Time Type Quantity Stock Price Currency
17:44:46 formt 250 $ 0.519 USD

VistaGen Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 28.90M 55.77M 55.62M $ - $ - -0.89 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 9.00 0.60%

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.5450.580.50970.5366273918,337-0.0268-4.92%
1 Month0.480.680.460510.5427071,275,1190.03827.96%
3 Months0.480.6850.350.4932337971,3370.03827.96%
6 Months0.71780.980.300.5185009615,479-0.1996-27.81%
1 Year0.7041.48620.100.6168433598,291-0.1858-26.39%
3 Years1.742.650.101.17581,712-1.22-70.22%
5 Years13.0014.050.101.22368,707-12.48-96.01%

VistaGen Therapeutics Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants.

Your Recent History
VistaGen T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.